共 134 条
[1]
Chen G(2021)Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: a real-world evidence study Clin Cardiol 44 1613-1620
[2]
Farris MS(2021)Lipid testing, lipid-modifying therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) inhibitor eligibility in 27 979 patients with incident acute coronary syndrome Circ Cardiovasc Qual Outcomes 14 1129-1150
[3]
Cowling T(2021)Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults Can J Cardiol 37 1440-1450
[4]
Pinto L(2020)Low-density lipoprotein cholesterol and adverse cardiovascular events after percutaneous coronary intervention J Am Coll Cardiol 76 e1082-e1143
[5]
Rogoza RM(2019)2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines Circulation 139 1366-1418
[6]
MacKinnon E(2022)2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk J Am Coll Cardiol 80 111-188
[7]
Sarak B(2019)2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Eur Heart J 41 1713-1722
[8]
Savu A(2017)Evolocumab and clinical outcomes in patients with cardiovascular disease N Engl J Med 376 1864-1872
[9]
Kaul P(2022)Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study Eur J Prev Cardiol 28 378-384
[10]
McAlister FA(2017)Recent temporal changes in atherosclerotic cardiovascular diseases in Ontario: clinical and health systems impact Can J Cardiol 33 499-502